{"id":"W3137447968","doi":"10.1200/jco.20.03175","title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Gastroenterology; Refractory (planetary science); Follicular lymphoma; Lymphoma; Rituximab; Adverse effect; CD20; Alemtuzumab; Oncology; T cell; Immunology; Immune system; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001032013,0.0008501643,0.0009096049,0.0002285437,0.0001938792,0.0005724069,0.0006674856,0.0007621218,0.001638165],"category_scores_gemma":[0.0003477144,0.0002372027,0.0007505503,0.0001941917,0.0005784379,0.0005797319,0.0002756749,0.00180957,0.0004381329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005311701,"about_ca_system_score_gemma":0.0004887287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004072902,"about_ca_topic_score_gemma":0.001060169,"domain_scores_codex":[0.9997851,0.00007963238,0.0000149772,0.0000426256,0.00002387024,0.00005378944],"domain_scores_gemma":[0.9996936,0.00003874815,0.00006432004,0.00002981499,0.00001414279,0.0001592569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3861126,0.03999283,0.01283507,0.001337729,0.002006667,0.0005407575,0.00060619,0.005409491,0.1849914,0.0007511943,0.007773397,0.3576427],"study_design_scores_gemma":[0.3951786,0.5458966,0.02104242,0.00008165481,0.0006994148,0.001191923,0.0001144443,0.003582247,0.02312931,0.0004017079,0.008628532,0.00005317801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939306,0.002666357,0.0005365922,0.00020297,0.00003869562,0.0008358601,0.0003605407,0.0001281434,0.001300161],"genre_scores_gemma":[0.9937006,0.001839593,0.0008711091,0.0005554322,0.00006918159,0.0006508533,0.0009957072,0.00002074597,0.001296789],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001638165,"threshold_uncertainty_score":0.00548023,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2659444738081362,"score_gpt":0.5123547411190288,"score_spread":0.2464102673108926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}